Navigation Links
Carrington Reports Second Quarter 2007 Results
Date:8/19/2007

- Revenues Down from Same Quarter Last Year - 17 Percent Quarter-to-Quarter Revenue Gain Evidences Start of Turnaround

for Core Business

- DelSite Signs Additional Agreements

IRVING, Texas, Aug. 14 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Nasdaq: CARN) reported revenue for the quarter ended June 30, 2007 of $5.6 million, compared to $6.5 million in the year ago period. The revenue in the quarter just ended, while 17 percent higher than the $4.8 million revenue reported for the first quarter of the current year, was shy of compensating for the expected 25 percent drop in Consumer Services division revenue from the year-ago quarter due mainly to the discontinuation of certain products and expiration of a key customer's materials supply agreement, as previously reported. Also as previously reported, a new, three-year supply agreement is now in place.

Medical Services revenue for the second quarter of 2007 remained essentially unchanged from the year-ago period, at $2.2 million. Grant income received for funding of research for the Company's wholly owned drug delivery subsidiary, DelSite Biotechnologies, Inc., increased by 13 percent for the quarter, to $398,000 from $352,000 a year ago.

Net loss for the second quarter of 2007, including $801,000 of net funding of DelSite, was $2.2 million, or 20 cents per basic and diluted share, remaining basically unchanged from the net loss reported for the year-ago quarter. Pro forma loss for the quarter, exclusive of DelSite net funding, was $1.4 million compared to a $1.2 million pro forma loss in the prior year period.

"The changes we initiated to bring growth and profitabilit
'/>"/>

SOURCE Carrington Laboratories, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Today, Americord Registry, one of the fastest growing cord ... a partner at Kirkland & Ellis LLP, as the newest ... http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about ... Martin Smithmyer , CEO of Americord. "He brings a wealth ... assist Americord,s growth and vision." Andrew Horne ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... does not sacrifice selectivity to achieve faster flow rates in comparison to nylon ... with significant open space to allow easy liquid flow while trapping particulates as ...
(Date:6/30/2015)... Oldsmar, FL (PRWEB) , ... June 30, 2015 , ... ... approximately 7.76% of Cryo-Cell’s currently outstanding common shares (including shares of unvested restricted stock). ... tender offer, the last sale price of Cryo-Cell’s shares reported on the OTCBB was ...
(Date:6/30/2015)... , June 30, 2015  The University of ... Biosciences (CCE/Bio) and UC San Diego Extension announced ... be held Aug.  12 – 14, 2015, at ... three-day workshop provides an intense exposure to best ... and is well-suited to biologists, process engineers and ...
Breaking Biology Technology:Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2
... July 7 VisEn Medical Inc., a leader in fluorescence ... commercial launch of its new Cat-K FAST ... activity associated with disease progression and therapeutic response in vivo ... biomarker and therapeutic target in a range of bone-related diseases, including ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... the generic version of AstraZeneca,s prostate cancer treatment Casodex(R), which ... 12 months ending March 31 for the same strength, according ...
... and SAN MATEO, Calif., July 7 King Pharmaceuticals, Inc. (NYSE: ... PTIE ) today announced that on July 2, 2009, King met ... Complete Response Letter regarding the New Drug Application (NDA) for REMOXY(R). ... path forward to resubmit the REMOXY(R) NDA and to address all ...
Cached Biology Technology:VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent 2King and Pain Therapeutics Announce REMOXY(R) NDA Update 2King and Pain Therapeutics Announce REMOXY(R) NDA Update 3
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... a recent academic review, a University of Minnesota professor in ... opposed to specific nutrients, may be key to having a ... in food industry and government, where marketers and regulators tend ... specific vitamins and added supplements in food products, not the ...
... and EUMETSAT, the European Organisation for the Exploitation ... provide essential launch control services for the last ... MSG-4. Under the agreement, ESA will provide ... orbit phase (LEOP), which involves moving the satellite ...
... P&G Beauty announced that they successfully sequenced the complete ... naturally occurring fungus responsible for the onset of dandruff ... the genome sequencing are published in todays online edition ... Dandruff and seborrheic dermatitis affect more than 50 ...
Cached Biology News:Foods, not specific nutrients, may be key to good health 2ESA to provide essential launch control services to EUMETSAT 2ESA to provide essential launch control services to EUMETSAT 3Scientists complete genome sequence of fungus responsible for dandruff, skin disorders 2Scientists complete genome sequence of fungus responsible for dandruff, skin disorders 3
... of use and flexibility of the BDTM LSR, the ... LSR II. The BD LSR II has performance, ... analyzer. Free up your high-performance cell sorter by ... the BD LSR II. The BD LSR II can ...
...
Fingerprinting II Informatix cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to ...
... Fingerprinting II identification and ... optional module that adds ... searches and identification of ... of entries of the ...
Biology Products: